Adjuvant treatment of breast cancer patients with trastuzumab
By: Erika Matos and Tanja Čufer
Open Access
|Dec 2007References
- Winer EP, Piccart-Gebhart MJ, Rugo HS, Sledge GW. Management of HER2-positive breast cancer. In: Perry MC, editor.Alexandria, VA: ASCO; 2006. p. 3-14.
- Gennari A, Sormani MP, Puntoni M,P. A pooled analysis on the interaction between HER-2 expression and responsiveness of breast cancer to adjuvant chemotherapy. [Abstract 41].2006;s9.
- Lipton A, Ali SM, Leitzel K, Chinchilli V, Engle L, Harvey HA, et al. Elevated serum Her2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.2002; 20: 1467-72.
- Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group.2005; 23: 4265-74.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.2001; 344: 783-92.
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.2007; 25: 118-45.
- Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial.2007; 369: 29-36.
- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.2005; 353: 1673-84.
- Perez ES, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer.[Abstract 512].2007;6s.
- Slamon D, Eiermann W, Robert N,, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in her2 positive early breast cancer patients: BCIRG 006 study.2005;s5.
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Bono P, Alanko T, Kataja V, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbin with or without trastuzumab for breast cancer.2005; 354: 789-90.
- Gelber RD.2005
- Paik S, Kim C, Joeng J, Geyer CE, Romond EH, Mejia-Mejia O, et al. Benefit from adjuvant trastuzumab may not be confined to patients with 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. [Abstract 511].2007;5s.
- Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.2005; 23: 7811-9.
Language: English
Page range: 115 - 122
Published on: Dec 6, 2007
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2007 Erika Matos, Tanja Čufer, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.